CoChat

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer

Open access
Paltoglou, Steve, Das, Rajdeep, Townley, Scott L., Hickey, Theresa E., Tarulli, Gerard A., Coutinho, Isabel, Fernandes, Rayzel, Hanson, Adrienne R., Denis, Iza, Carroll, Jason S., Dehm, Scott M., Raj, Ganesh V., Plymate, Stephen R., Tilley, Wayne D., Selth, Luke A. · 2017 · Cancer Research
Cited by 112

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer is an important mechanism driving disease progression and therapy resistance. Using a novel proteomic technique, we identified a new AR coregulator, the transcription factor Grainyhead-like 2 (GRHL2), and demonstrated its essential role in the oncogenic AR signaling axis. GRHL2 colocalized with AR in prostate tumors and was frequently amplified and upregulated in prostate cancer. Importantly, GRHL2 maintained AR expression in multiple prostate cancer model systems, was required for cell proliferation, enhanced AR's transcriptional activity, and colocated with AR at specific sites on chromatin to regulate genes relevant to disease progression. GRHL2 is itself an AR-regulated gene, creating a positive feedback loop between the two factors. The link between GRHL2 and AR also applied to constitutively active truncated AR variants (ARV), as GRHL2 interacted with and regulated ARVs and vice versa. These oncogenic functions of GRHL2 were counterbalanced by its ability to suppress epithelial–mesenchymal transition and cell invasion. Mechanistic evidence suggested that AR assisted GRHL2 in maintaining the epithelial phenotype. In summary, this study has identified a new AR coregulator with a multifaceted role in prostate cancer, functioning as an enhancer of the oncogenic AR signaling pathway but also as a suppressor of metastasis-related phenotypes. Cancer Res; 77(13); 3417–30. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-1616

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 112

Metadata

Authors
Paltoglou, S., Das, R., Townley, S. L., Hickey, T. E., Tarulli, G. A., Coutinho, I., Fernandes, R., Hanson, A. R., Denis, I., Carroll, J. S., Dehm, S. M., Raj, G. V., Plymate, S. R., Tilley, W. D., & Selth, L. A.
Venue
Cancer Research
Published
2017-07-01
Volume
77
Issue
13
Pages
3417-3430
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2611178729
Cited by
112
References
6
FWCI
6.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1616
The paper
Paltoglou, S., Das, R., Townley, S. L., Hickey, T. E., Tarulli, G. A., Coutinho, I., Fernandes, R., Hanson, A. R., Denis, I., Carroll, J. S., Dehm, S. M., Raj, G. V., Plymate, S. R., Tilley, W. D., & Selth, L. A. (2017). Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.